Arteris, Inc. (NASDAQ:AIP) President and CEO Charles K. Janac has recently sold a portion of his holdings in the company. According to the latest filings, Janac sold a total of 3,303 shares of common stock at prices ranging from $7.57 to $7.68, with an average price of $7.6265 per share, netting a total of $15,718 from the sale. Additionally, another set of 1,242 shares were sold at a price of $7.8125 each, amounting to $9,703.
The transactions were conducted on June 4, 2024, and were disclosed in a Form 4 filing with the Securities and Exchange Commission on June 6, 2024. Notably, a portion of the shares sold by Janac was to satisfy tax liabilities arising from the release of restricted stock units, as indicated in the footnotes of the filing. Another part of the sales was made pursuant to a pre-arranged 10b5-1 trading plan, which allows company insiders to sell shares at predetermined times to avoid accusations of insider trading.
Following these transactions, Janac still holds a substantial number of shares in Arteris. The SEC filing showed that he has a direct ownership of 315,341 shares after the sales. Additionally, Janac is associated with indirect holdings through Bayview Legacy, LLC, and the Charles & Lydia Janac Trust, with the former holding over 10 million shares and the latter holding 63,252 shares.
The sales come at a time when Arteris, a semiconductor company incorporated in Delaware, continues to navigate the highly competitive tech industry. The company specializes in the design and development of network-on-chip interconnect semiconductor intellectual property for system-on-chips in consumer electronics, mobile, automotive, and other markets.
Investors and stakeholders of Arteris typically monitor insider transactions as they may provide insights into an executive's confidence in the company's future performance. However, it's worth noting that insider sales can occur for various reasons and may not necessarily reflect a negative outlook.
In other recent news, Arteris, Inc. reported its Q1 2024 results, indicating a slight decrease in total revenue but achieving positive free cash flow and securing significant licensing deals. The company's annual contract value plus royalties stood at $58.2 million, with a non-GAAP operating loss of $5.3 million. Furthermore, Arteris anticipates its ACV plus royalties to range between $58 million and $62 million for Q2, with projected revenue between $13.2 million and $14.2 million.
In addition to financial results, Arteris secured several significant licensing deals, half of which are aimed at enabling AI and machine learning design starts. The company also expanded its collaboration with Arm, demonstrating a strategic initiative to capitalize on the growing demand for advanced AI chips.
In a separate development, Northland reiterated its Outperform rating on Arteris, maintaining a price target of $14.00. Northland's rating reflects confidence in Arteris's strategic direction and its potential for continued success in the evolving system on chip (SoC) market. The company's growth is propelled by the increasing complexity of SoC, a rise in the number of SoC designs, a shortage of chip designers, and a notable transition from captive to merchant system IP markets.
InvestingPro Insights
In light of the recent insider transactions at Arteris, Inc. (NASDAQ:AIP), it's pertinent to delve into the company's financial health and market performance for a broader understanding of its current standing. The InvestingPro data reveals that Arteris holds a market capitalization of approximately $305.52 million, which provides a sense of the company's size within the semiconductor space. Despite challenges in profitability, as indicated by a negative P/E ratio of -7.96, the company's impressive gross profit margin stands at a notable 89.86% for the last twelve months as of Q1 2024. This margin reflects the company's ability to maintain a significant markup on its products, a positive sign for potential cost management and pricing power.
However, it's important to note that Arteris has not been profitable over the last twelve months, and analysts do not expect the company to be profitable this year. This aligns with the reported operating income margin of -66.44% for the same period, emphasizing the company's current inability to translate its high gross margins into net earnings. Additionally, the stock has experienced a substantial 14.9% decline in the last month, which may have influenced the timing of the CEO's stock sale.
For those considering an investment in Arteris, one of the InvestingPro Tips highlights that the company is trading at a high Price / Book multiple of 32.45, suggesting a premium valuation relative to its book value. Moreover, Arteris does not pay a dividend, which may impact the investment decision for income-focused investors. On a positive note, the company holds more cash than debt on its balance sheet, which may provide some financial flexibility in its operations and investment strategies.
For further insights and a complete list of tips, readers may consider subscribing to InvestingPro, where they can discover additional InvestingPro Tips to aid in their investment analysis. Use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. Currently, there are 9 additional tips available on InvestingPro for Arteris, which can provide a deeper dive into the company's financial nuances and market potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.